Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy

Experimental Hematology

Volumn 39, Issue 9, 2011, Pages

  Niam, Madelaine ^a   Linn, Yeh Ching ^b   Fook Chong, Stephanie ^b   Lim, Tsyr Jong ^a   Chu, Sixian ^a   Choong, Alicia ^a   Yong, Hao Xiang ^b   Suck, Garnet ^a   Chan, Marieta ^a   Koh, Mickey ^a  

^a HEALTH SCIENCES AUTHORITY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL CULTURE; CELL EXPANSION; CELL GROWTH; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DONOR; FROZEN SECTION; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THAWING;

EID: 80051470922     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.06.005     Document Type: Article

References (21)

1. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
2. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
3. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice
4. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts
5. Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy
6. Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation
7. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
8. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
9. [The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia]
10. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
11. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell
12. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells
13. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells
14. Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells
15. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies
16. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
17. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia
18. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
19. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation
20. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells
21. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner